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The novel coronavirus (SARS-Cov-2) that was first reported in Wuhan, China and provokes the COVID-
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governments have enforced social isolation protocols on their citizens, which has led to the closure of 
many large public gatherings in order to limit the spread of the virus.  These closures could reasonably be 
expected to affect blood collections, thereby presaging shortages of blood for transfusion. On the other 
hand, steps such as the postponement of elective surgeries and other non-urgent transfusions could 
mitigate against potential shortfalls in the blood supply.[1] 
 The transfusion community has faced epidemics and pandemics before,[2-9] but little has been 
published about the preparations made by hospital-based transfusion services for handling samples and 
performing pretransfusion testing on patients who are affected by the disease.  A study of the policies and 
procedures vis-à-vis pre-transfusion testing and the provision of blood products at three Japanese 
hospitals during the recent Ebola epidemic revealed different approaches to performing pre-transfusion 
testing on potential recipients and how the blood products were issued.[10] Given the urgent need to 
develop best practices for conducting pre-transfusion testing and issuing blood products not just during 
the current novel coronavirus pandemic but also for future pandemics, the time is now propitious to 
understand how transfusion services in cities with different burdens of this disease are approaching these 
issues and for the dissemination of different policies and procedures that facilitate the timely provision of 
blood products to our patients while maintaining a high level of safety for transfusion service staff.  
 
Summary of Responses 
 
Question 1: Demographics of respondents 
Responses were received from a total of 12 centers from around the world including Australia, Brazil, 
Canada, Denmark, Iran, Israel, Italy, Japan, Korea, Spain, UK, and USA.  Table 1 demonstrates the 
demographics of the respondents and the cities in which their institutions were located.  All respondents 
worked in large academic medical centers, although the Brazilian respondent worked at a hospital that 
only treated hematology oncology patients and the Iranian respondent worked in a private specialty 
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from a low of 4,831 (Israel) to a high of 386,817 (USA), but accounting for the population of each 
country, the rate of confirmed cases ranged from 0.01% (Brazil and Japan) to 0.30% (Italy).  The rate of 
coronavirus infections was felt to be increasing in Israel, USA, Canada, Japan, and Brazil, stable in the 
UK, and Korea, and decreasing in Spain, Denmark, Australia, and Italy.  However, the survey responses 
were received between 31 March, 2020 and 24 April, 2020, so the number of confirmed cases and the 
respondent’s opinion as to the extent of the spread of coronavirus throughout their country reflected the 
state of the disease at the time the survey was completed; this number and opinion might have changed in 
the time between survey completion and the publication of this International Forum.   
 Table 2 presents a short summary of each respondent’s answer to each question. 
 
Question 2: Did your hospital blood bank/transfusion service accept samples for pre-transfusion testing 
(including DAT) from patients who were confirmed or suspected to be infected with novel coronavirus? 
All of the respondents indicated that their transfusion services accepted samples from patients with 
confirmed or suspected coronavirus infections.  The American, Australian, Iranian, and Japanese 
respondents indicated that they did not make any changes to the processes of sample procurement and 
labeling, accepting the sample in the transfusion service, testing, storing, or discarding the sample. 
For the centers that did institute new policy changes for handling these samples, the Israeli and Korean 
respondents indicated that the sample label had the word COVID written on it to alert the technologists to 
implement the enhanced safety measures for handling and testing these samples, and the samples were 
transported to the transfusion service in clear plastic bags.  The Italian respondent indicated that the 
labeling was performed outside of the patient’s room in a designated safe area. 
 The Spanish respondent indicated all samples that were received at the transfusion service for pre-
transfusion testing were assumed to be potentially contaminated with coronavirus and so they were all 
cleaned with hypochlorite before being processed, and they were also UV irradiated for 30 minutes.  
Similarly, the Danish respondent indicated that samples from coronavirus patients were cleaned by the 
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that paper requisitions were sealed in plastic bags for 5 days to sanitize them before being archived.  At 
the Brazilian and Canadian respondents’ sites, all samples regardless of the presence of coronavirus were 
opened behind a plastic shield, while in a similar vein, at the UK respondent’s site, the sample tubes were 
left for a while to settle after centrifugation so as to reduce the probability of aerosolizing the contents.  
Also, at the Canadian site, all laboratory staff wore face masks as maintaining appropriate physical 
distancing is not always possible. 
 All of the respondents indicated that the samples were tested in the usual location in the transfusion 
service except for the Israeli respondent who indicated that pre-transfusion testing was performed in a 
biosafety cabinet and the Korean respondent who indicated that the samples were tested in a fume hood. 
 In terms of the personal protective equipment (PPE) that was worn by the transfusion service 
technologists, the Spanish, American, Brazilian, Danish, Australian, and British respondents indicated 
that the standard laboratory PPE was worn when testing these samples.  The Israeli respondent indicated 
that double gloves, goggles, an N95 respirator, and a gown was worn when testing samples from known 
or suspected coronavirus patients, while the Italian respondent indicated that a mask was added to the 
standard PPE when testing such a sample.  At the Korean respondent’s transfusion service, gloves, 
goggles, and a surgical mask were worn when testing these samples. 
 Once the pre-transfusion testing had been completed, most of the respondents stored these samples in 
their routine manner, expect at the Israeli respondent’s laboratory where the samples were stored in a 
separate shelf in a sealed container, and at the Italian respondent’s laboratory where the samples from 
known or suspected coronavirus patients were kept in a dedicated rack in the same refrigerator as the 
other samples.  The Korean respondent indicated that the samples were returned to the plastic bag into 
which they were received for storage, and when it was time to dispose of the samples they were sent to 
their department of microbiology for disinfection and disposal.  All of the other respondents indicated that 
the samples were discarded following their routine protocol. 
 Lastly, as stated above, all of the respondents indicated that their transfusion services accepted 
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prior to receiving the biosafety cabinet, samples from these patients were not accepted for pre-transfusion 
testing. Instead, group O RBCs and group AB plasma would have been issued to these patients.  All of 
the patient’s available transfusion and immunohematological history was reviewed prior to issuing blood 
products, and antigen negative RBCs would have been issued to an alloimmunized recipient.  
Uncrossmatched RBCs were rarely required in this setting as the biosafety cabinet was available quickly 
after the need for it arose. 
 
Question 3: If a cooler (i.e., a temperature controlled device used for storing blood products outside of 
the blood bank) of blood products was issued on such a patient how did the transfusion service handle the 
cooler? 
The American respondent indicated that blood products were loaded into the cooler in the routine manner 
for patients with known or suspected coronavirus, while the Australian respondent indicated that RBCs 
were individually put into bags and then loaded into the cooler.  These coolers always remained outside of 
the patient’s room, thus the cooler did not need to be decontaminated upon its return to the transfusion 
service.  RBCs that were taken into a patient with known or suspected coronavirus’ room but not 
transfused were discarded if they were returned to the blood bank.  The Canadian respondent also issued 
RBCs in individual plastic bags that had been sealed to indicate if the bag had been opened; at this center, 
coolers were decontaminated upon return to the transfusion service, which had been the routine practice 
before this pandemic, and any RBCs that were returned in unopened plastic bags were returned to the 
inventory; RBCs that were returned in opened bags were discarded.  The Australian and Canadian policy 
of issuing RBCs in individual plastic bags in a cooler were new policies that were implemented during 
this pandemic.  The American and Italian respondents indicated that RBCs that were returned in a cooler 
were wiped down and restocked.  The Canadian, American, and Brazilian respondents indicated that the 
coolers were also disinfected, with the latter indicating that this was a new policy that had been 
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 The Spanish and British respondents indicated that they did not make any changes to their cooler 
issuing policy, while the Israeli, Danish, Italian, and Korean respondents indicated that they do not 
routinely issue coolers to any patient. 
 
Question 4: Does your facility have an existing plan to deal with samples from patients with novel 
pathogens? 
Many of the respondents indicated that they had a pre-existing plan for handling samples from patients 
with novel pathogens.  For example, the Israeli plan was derived from their experience with the 2003 
SARS outbreak, the Korean respondent’s plan was based on their experience with the MERS outbreak, 
and the Canadian respondent’s plan was based on the Ebola virus outbreak.  The Spanish respondent 
indicated that the hospital had a plan but that it had been dormant before it was reactivated for this 
pandemic, while the Danish respondent indicated that their pre-existing plan was designed for patients 
who were contaminated with radiation, chemical or biological agents.  Both the American and Italian 
respondents indicated that they did not have a specific plan for dealing with novel pathogens because 
standard universal precautions were always being used for all samples.  Both the Brazilian and the British 
respondents indicated that their hospitals did not have a pre-existing plan. 
 
Question 5: Was any additional training provided to the staff about the nature of this virus and its 
infectivity? 
All of the respondents indicated that some form of training was provided to their transfusion service 
technologists and/or hospital house staff.  The training generally involved education about the proper use 
of PPE and the application of universal precautions, as well as reminders about the importance of 
handwashing and frequent surface disinfection.  The Israeli and British respondents provided specific 
education about how to use the biosafety cabinet and about the new policy of not immediately opening 
the centrifuged samples, respectively.  See the individual responses for more details about the specific 
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Question 6:  How has the utilization of red blood cells, platelets and plasma in your hospital changed 
since the start of the pandemic? 
Only the Australian and Korean respondents indicated that the use of RBCs, plasma, and platelets were 
unchanged from pre-pandemic levels. The other respondents indicated that they had either quantitatively 
or qualitatively noticed reductions in transfusions at their centers of around 30% for RBCs, 20-47% for 
platelets, and about 40% for plasma.  Not surprisingly, the Brazilian respondent whose hospital 
exclusively treats hematology oncology patients reported no change in platelet transfusions thus far in the 
pandemic. 
 
Question 7: Does the respondent anticipate blood product shortages as a result of this pandemic? 
The Israeli, Spanish, Danish, British, and Korean respondents did not expect a blood shortage as a result 
of this pandemic.  Others, such as the Brazilian, Italian and Iranian respondents, expected shortages in the 
short, medium, and long terms, while the American, Australian, Canadian, and Japanese respondents 
expected medium term shortages.  The Canadian respondent also expects a shortage of plasma 
fractionation products such as IvIg in the long term. 
 In terms of shortage mitigation strategies, many respondents such as the Israeli, Australian, and 
Italian respondents indicated that their hospitals had cancelled elective surgeries thereby helping to 
preserve their blood product inventories.  Others, such as the respondents from USA, Brazil, Australia, 
and Canada held information campaigns to remind clinicians about appropriate transfusion thresholds and 
transfusing a single RBC unit at a time. The Canadian respondent also indicated that they reminded their 
clinicians about the appropriate use of pharmaceuticals such as prothrombin complex concentrates, 
tranexamic acid, and intravenous iron.  The British respondent indicated that they reduced their hospital’s 
blood inventory level by about 30% to reduce wastage. 
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See the individual responses for more details.  In general, the advice from the respondents was to plan 
ahead of time for how the transfusion service should respond when these events happen.  The Spanish and 
Canadian respondents mentioned their lack of advance preparedness for implementing a convalescent 
plasma program, while the Brazilian respondents advised having a plan for employee travel to and from 
the hospital when public transport is unavailable and for dealing with reduced staffing due to illness.  The 
Italian respondent was concerned about having too many people donate blood early in the pandemic when 
the need for products was low thereby potentially creating waste and making donors ineligible to donate 
as the pandemic wanes and demand returns to normal.  The British respondent suggested keeping the 
workflow as routine as possible to avoid confusion and errors. 
 
Question 9: Will your center offer convalescent plasma (CP)? 
The Spanish, Canadian, and British respondents indicated that CP will be available in the context of a 
clinical trial; the multicenter Spanish trial will randomize 278 patients into either the standard of care or 
standard of care plus CP arms, and primarily use clinical outcomes such as if the patient needs 
hospitalization and if any supplemental oxygen is required.  Patients in the CP arm will receive one unit 
that will be between 250-300 ml collected by any approved apheresis machine, and the plasma will 
undergo pathogen inactivation using any approved method.  Details of the Canadian and British trials are 
provided in the response section.  The American respondent also plans to offer CP in the context of a 
clinical trial an also for compassionate use without pathogen inactivation.  The Israeli and Brazilian 
respondents indicated that the Intercept (Cerus) technology will be used for their CP, while the 
respondents in Denmark, USA, and the UK indicated that the CP will not undergo pathogen inactivation.  
At the time of survey completion, CP was not available in Australia, Korea, and Japan. 
 
Summary 
Among countries with different levels of people affected by the SAR-Cov 2 pandemic, the hospital blood 
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not change their policies/procedures for samples received from known or suspected patients while the 
remainder changed their practice in some way to minimize the exposure to potential contaminated 
specimens. Interestingly 75% of the respondents reported a decrease in overall blood components 
utilization due to the changes introduced at the hospitals to treat the COVID-19 patients. Convalescent 




Table 1.  Demographics of the respondents to this International Forum. 
Table 2.  Summary of replies to the questions posed in this International Forum. PPE: Personal protection 
equipment. BSC: Biosafety cabinet. 
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1a. Country/City 1b. Type of Hospital
1c. Number of 
Beds
1.d Approximate 











1g. Were novel 
Coranavirus Cases 
Increasing, Decreasing or 





1639 22190 6553 (67) 25.65 Decreasing 
Rio de Janeiro, Brazil
Academic medical 
center




1355 10500 42110 (2149) 37.6 Increasing 
























1989 59838 10674 (236) 51.78 Stable




















2. Did your hospital blood bank/transfusion 
service accept samples  from patients confirmed 
or suspected to be infected with novel 
coronavirus?
2h. Were changes made in testing 
policies/procedures for samples 
from known or suspected patients?
2i. If yes, what changes? 
2j. Changes made for all 
samples or only for known or 
suspected cases? 
3. Were blood 
products dispensed 
in coolers?
3l-o. Changes made for 
products dispensed/returned in 
coolers
4. Did your facility have an existing 
plan to deal with samples from 
patients with novel pathogen?
5. Was any additional training 
provided to the staff about the 
nature of this virus and its 
infectivity?
6. Overall blood product use since 
the start of pandemic increasing, 
decreasing or stable?
7. Do you 
anticipate blood 
shortages at your 
hospital?
8. Describe specific measures 
to avert or minimize these 
shortages
9. Are you planning to 
use/using convalescent 
plasma from COVID-19 
patients to treat severe 
forms of the disease?
Melbourne, Australia Yes No NA NA Yes
Cooler remains outside patient 
room. Products discarded if 
taken into patient room and not 
transfused. 
Yes
Yes, use of PPE and laboratory 
disinfection protocols
Stable Yes
Cancellation of elective 
surgeries, enforcement of 
single unit transfusions in 
non-bleeding patients
Yes
Rio de Janeiro, Brazil Yes Yes Plastic film used to open tubes All No NA No
Yes, unspecified training session 
for staff
Decreasing No NA Yes
Toronto, Canada Yes Yes
Addition of splash guard for 
decapping samples
All Yes
Units placed in individual 
plastic bags and sealed with a 
sticker to indicate integrity, 
coolers disinfected upon return
Yes, created in response to Ebola
Yes, town hall on risk to lab staff 
from handling COVID samples 
Decreasing Yes
Maximize use of iv iron, TXA, 
epo, PCCs and strict adhesion 
to strict transfusion triggers
Yes
Odense, Denmark Yes Yes
Samples from infected or 
potentially infected patients were 
externally cleaned before arriving 
at transfusion service
Only COVID patients No NA No
Yes, e-learning program 
concerning hand hygiene and 
infection prevention
Decreasing No NA Yes
Tehran, Iran Yes No NA NA Yes NA Not specified
Yes, nature of training not 
specified
Decreasing Yes
Cancellation of elective 
surgeries, adopting more 
restrictive transfusion 
thresholds
Yes, but not at respondent's 
hospital
Be'er Yaakov, Israel Yes Yes
Labeled as COVID suspected, 
received in biohazard packages, no 
tubing of specimens, sample tested 
in BSC, additional PPE used by staff, 
samples stored on designated shelf
Only COVID patients No NA
Yes, created in response to SARS in 
2003
Yes. Use of new PPE and BSC Stable No NA Yes
Udine, Italy Yes Yes
Surgical mask added to PPE and 
samples placed in segregated 
storage
Only COVID patients No NA No Yes, unspecified online courses Decreasing Yes
Decrease of non-urgent 
surgeries and admissions, 
use of restrictive transfusion 
triggers 
No 
Tokyo, Japan Yes No NA NA Yes No 
Yes, samples are sent to the 
National Institute of Infectious 
Diseases
Yes, general hospital wide 
education
Decreasing Yes No current plan No 
Seoul, Korea Yes Yes
Sample bags labeled as possible 
COVID patient , samples tested in 
fume hood, stored in labeled bag 
and sent to micro for disinfection 
and disposal
Only COVID patients No NA
Yes, created in response to MERS in 
2015
Yes, unspecified hospital wide 
training
Stable No NA No 
Madrid, Spain Yes Yes
Sample tubes underwent 
hypochlorite  wiping and UV light 
treatment for 30 minutes.
All Not specified NA Yes, but it had been inactive
Yes, workers trained according to 
their risk assessment. 
Decreasing No NA Yes
Oxford, UK Yes Yes
Testing delayed after centrifugation 
to minimize aerosol droplets
Only COVID patients Yes Not specified Yes
Yes, education on testing 
procedure changes
Decreasing No NA Yes
Stanford, United 
States
Yes No NA NA Yes No No
Yes, assigned lesson and 
corresponding quizzes for lab 
guidelines
Decreasing Yes
Reinforce good transfusion 
practices
Yes
